49th week of 2008 patent applcation highlights part 40 |
Patent application number | Title | Published |
20080299112 | Human Polyclonal Antibodies from Genetically Engineered Animals - Substantially human antisera are provided by genetically modifying a domestic animal generally weighing at least about 1 kg. The domestic animal is genetically modified by generating inactive heavy and light chain immunoglobulin loci and integrating at least functional portions of the human heavy and light chain immunoglobulin loci, whereby the human loci generate an immune response. The antisera find use in the treatment of diseases, immunocompromised patients and in case of transplantation. | 2008-12-04 |
20080299113 | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents - The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and an IGF1R inhibitor compound of Formula I combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of an EGFR kinase inhibitor and IGF1R inhibitor compound of Formula I combination with a pharmaceutically acceptable carrier. The IGF1R inhibitor is represented by Formula I: | 2008-12-04 |
20080299114 | HUMANEERED ANTI-FACTOR B ANTIBODY - This invention relates to humaneered anti-factor B antibodies and antigen-binding fragments thereof with reduced immunogenicity. The humaneered anti-factor B antibodies and antigen-binding fragments thereof are derived from murine monoclonal antibody 1379, which binds factor B in the third short consensus repeat (“SCR”) domain and selectively inhibits activation of the alternative complement pathway by preventing formation of the C3bBb complex. The invention also relates to methods of treating diseases or disorders in which activation of the alternative complement pathway plays a role, and methods of selectively inhibiting activation of the alternative complement pathway in an individual in need thereof. | 2008-12-04 |
20080299115 | Antibody Variants with Faster Antigen Association Rates - Antibody variants with faster antigen association rates are disclosed. The antibody variants have one or more amino acid alteration(s) in or adjacent to at least one hypervariable region thereof which increase charge complementarity between the antibody variant and an antigen to which it binds. | 2008-12-04 |
20080299116 | Vascular Endothelial Cell Growth Factor Antagonists and Uses Thereof - The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided. | 2008-12-04 |
20080299117 | Treatment Method - The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies of 100 mg to 200 mg effective to deplete B cells in the patient. | 2008-12-04 |
20080299118 | FXR Agonists for the Treatment of Malignancies - Provided are certain methods of treating maligancies with farnesoid X receptor agonists. Also provided are certain methods of inducing RECK gene expression with farnesoid X receptor agonists and methods of reducing at least one feature of a cell with farnesoid X receptor agonists | 2008-12-04 |
20080299119 | POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue. | 2008-12-04 |
20080299120 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 2008-12-04 |
20080299121 | Multivalent recombinant antibodies for treating HRV infections - The present invention relates to high affinity multivalent recombinant antibodies and multivalent peptides against ICAM-1 and/or LDL receptor and pharmaceutical compositions containing such multivalent antibodies or multivalent peptides. The present invention also relates to methods of using such multivalent antibodies or multivalent peptides to prevent and treat human rhinovirus infection and diseases and pathological conditions associated therewith. | 2008-12-04 |
20080299122 | Modulating immune responses - The invention provides methods for modulating the immune system using anti-CD83 antibodies that can influence CD83 function. | 2008-12-04 |
20080299123 | TREATMENT OF CHEMOTHERAPY- OR RADIOTHERAPY-RESISTANT TUMORS - The present invention relates to the use of L1 interfering molecules, especially anti-L1 antibodies, in tumor treatment. Especially, the present invention relates to the use of said L1 interfering molecules in sensitizing tumor cells for the treatment with chemotherapeutic drugs of with radiotherapy and to the combined administration of L1 interfering molecules with chemotherapeutic drugs or with radiotherapy. | 2008-12-04 |
20080299124 | NOVEL METHOD FOR THE STABILIZATION OF CHIMERIC IMMUNOGLOBULIN OR IMMUNOGLOBULIN FRAGMENTS AND, AND STABILIZED ANTI-EGP-2 SCFV FRAGMENT - The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment. | 2008-12-04 |
20080299125 | Genetic basis of treatment response in depression patients - The invention provides a collection of polymorphic sites associated with response to treatment by an SSRI or placebo in depression patients. The polymorphic sites and others in linkage disequilibrium with them are useful in determining whether to treat a patient with an SSRI or include a patient in a clinical trial to test an SSRI. | 2008-12-04 |
20080299126 | Anti-Myostatin Antibodies - A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species. | 2008-12-04 |
20080299127 | PROTECTIVE STAPHYLOCOCCUS AUREUS VACCINE BASED ON CELL WALL-ASSOCIATED PROTEINS - The present invention relates to a pharmaceutical composition or a medicament, notably a protective | 2008-12-04 |
20080299128 | Effect of Bst2 on inflammation - The application disclose a method of preventing immune cells from binding to other cells, which includes contacting the immune cells and the other cells with a composition comprising Bst2 antagonist. | 2008-12-04 |
20080299129 | ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 AND METHODS OF USE - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. | 2008-12-04 |
20080299130 | Methods And Compositions For The Treatment Of Ocular Neovascularization - The invention relates to compositions and methods for the treatment or prevention of ocular neovascularization by reducing macrophage infiltration into the eye. The compositions of the invention include an antagonist of MCP-1 and/or CCR2 that blocks MCP-1 binding to or activation of CCR2y. | 2008-12-04 |
20080299131 | Anti-Viral Compositions - The invention provides a composition comprising for simultaneous, sequential or separate administration a) a polyanion; and b) an antibody reactive against an antigen on the surface of an intracellular form of a virus, which virus has an extracellular form that is surrounded by one lipid membrane more than the intracellular form. The present inventors have found that the compositions according to the invention comprising an antibody and a polyanion can neutralize virus infectivity more efficiently than other compositions reported hitherto. | 2008-12-04 |
20080299132 | Synergistic compositions for treating HIV-1 - Synergistic pharmaceutical compositions for treating or preventing HIV-1 infections comprising anti-CCR5 monoclonal antibodies and CCR5 antagonists, viral fusion inhibitors or viral attachment inhibitors are disclosed. The compositions exhibit significant greater activity than is anticipated from the activity of either component alone. Also provided are methods for treating or preventing HIV-1 using the same. | 2008-12-04 |
20080299133 | Anti-Il-12 Antibody Based Vectors, Host Cells, and Methods of Production and Uses - Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids. | 2008-12-04 |
20080299134 | Recombinant Anti-Interleukin-9 Antibodies - The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1. | 2008-12-04 |
20080299135 | METHODS AND COMPOSITIONS FOR NERVE REGENERATION - Methods and compositions for modulating growth of a neuron with a Wnt, a Wnt-like substance, and/or a chemical compound affecting a Wnt signaling pathway are disclosed. Also disclosed are methods for identifying a substance that modulates growth of a neuron by obtaining a candidate substance and contacting the candidate substance with the neuron are disclosed and methods for modulating growth of a neuron in a subject using a Wnt, a Wnt-like substance, and/or a chemical compound affecting a Wnt signaling pathway. The Wnt, Wnt-like substance, and/or chemical compounds affecting a Wnt signaling pathway can be delivered to the subject using gene therapy techniques. Also disclosed are pharmaceutical compositions for modulating growth of a neuron in a mammal that include a Wnt or a Wnt-like substance. Methods and compositions for inhibiting growth of a neuron are also disclosed. | 2008-12-04 |
20080299136 | WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS - The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer. | 2008-12-04 |
20080299137 | Fusion Proteins That Bind Effector Lymphocytes And Target Cells - Novel fusion proteins that comprise a first portion that corresponds to an antibody-like protein that is specific for an activating receptor on an effector lymphocyte or a variant thereof and a second portion that corresponds to a portion of a cell membrane protein and that binds to a cell-associated target are provided, as are methods of producing such fusion proteins, uses and methods involving such fusion proteins, and compounds and compositions related to such fusion proteins. | 2008-12-04 |
20080299138 | Toll-Like Receptor 3 Modulators and Uses Thereof - Modulators of TLR3 activity and their use are disclosed. | 2008-12-04 |
20080299139 | MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 2008-12-04 |
20080299140 | Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition - Immunogenic composition comprising at least one Herpes Simplex Virus type 1 (HSV-1) and/or type 2 (HSV-2) peptide sequence hearing at least one epitope from glycoprotein D (gD) and/or glycoprotein B (gB), a pharmaceutical carrier and/or a human compatible adjuvant, peptide sequences and uses thereof for prevention or treatment of an HSV condition. | 2008-12-04 |
20080299141 | Raccoon Poxvirus Expressing Genes of Porcine Virus - The present invention relates to a new recombinant raccoon poxvirus vector vaccine in which the vector expresses one or more antigenic proteins encoded by multiple open reading frames, preferably the ORF5, ORF6 and/or ORF3/ORF4/ORF7, of one or more porcine reproductive and respiratory syndrome virus strains alone or in combination with an open reading frame of porcine circovirus type 2 (PCV-2), preferably ORF2, at the hemagglutinin (ha) and/or thymidine kinase (tk) loci. | 2008-12-04 |
20080299142 | COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a | 2008-12-04 |
20080299143 | Cryptosporidium parvum antigens, antibodies thereof and diagnostic and therapeutic compositions thereof - Cloning and expression of genes encoding | 2008-12-04 |
20080299144 | GRASS BASED AVIAN DETERRENT - The invention relates to uses and methods relating to grass and endophyte combinations to repel avian species from the grass and endophyte combination. In particular, methods are described to select grass and endophyte combinations in order to enhance or maximise the repellent effect. Preferred endophyte and grass combinations are described which are based on the selection methods and include AR4, AR5, AR8 and AR94 (Deposit Nos. V07/029054, V07/029055, V071029056, V07/029057) in | 2008-12-04 |
20080299145 | Formula for improving physical performance and related methods - The present invention generally relates to the use of a formula that improves human and animal endurance, stamina, performance and other physical parameters. In one composition aspect, the formula or composition of the present invention includes a | 2008-12-04 |
20080299146 | SATIATING DIETETIC PRODUCT - The invention concerns a dietetic product belonging to the family of food products, complements or supplements for slimming or anti-obesity and appetite-suppressing or satiating food products, complements or supplements containing an efficient dose of food proteins, 70% of which at least are hydrolysed yeast proteins. The invention also concerns the use of the dietetic product in an aesthetic slimming diet. The invention further concerns the use of hydrolysed yeast proteins in the preparation of such a dietetic product. | 2008-12-04 |
20080299147 | Microalgae-Derived Compositions For Improving The Health And Appearance Of Skin - Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin. | 2008-12-04 |
20080299148 | Novel antitoxin and vaccine platform based on nodavirus VLPS - Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided. | 2008-12-04 |
20080299149 | Raccoon Poxvirus Expressing Genes of Feline Antigens - The present invention relates to new recombinant raccoon poxvirus vectors comprising two or more exogenous nucleic acid molecules, each encoding at least one feline protein, wherein at least two of the nucleic acid molecules are inserted into the hemagglutinin (ha) locus or the thymidine kinase (tk) locus, or at least one of the nucleic acid molecules is inserted into each of the hemagglutinin and thymidine kinase loci. Described herein are monovalent and polyvalent recombinant feline vaccines that encompass an immunologically effective amount of the recombinant raccoon poxvirus vectors and, optionally, a suitable carrier or diluent. The vaccine of this invention optionally includes additional feline antigens to provide broad spectrum protection to cats against a variety of feline pathogens. The invention further concerns the method for inducing a protective immune response to the feline pathogens in a cat by administering the recombinant vaccines. | 2008-12-04 |
20080299150 | METHOD AND SYSTEM FOR PROCESSING IMMUNO-COMPETENT CELLS IN VIEW OF AN ANTIVIRAL THERAPY, AND RELATED THERAPEUTIC PROCESS - A method for processing immuno-competent cells in view of an antiviral therapy on a human or animal subject, includes: | 2008-12-04 |
20080299151 | Influenza vaccines - Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed. | 2008-12-04 |
20080299152 | Norovirus Vaccine Formulations - The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups. | 2008-12-04 |
20080299153 | B. ANTHRACIS PREVENTION AND TREATMENT: MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION - The present invention pertains to the discovery that | 2008-12-04 |
20080299154 | COSMETIC HAIR COMPOSITIONS CONTAINING METAL-OXIDE LAYERED PIGMENTS AND METHODS OF USE - The disclosure relates to cosmetic hair compositions containing metal-oxide layered pigments. The disclosure also relates to the use of the metal-oxide layered pigments in cosmetic hair compositions. The disclosure also relates to compositions containing film-formers and stabilizers in combination with the metal-oxide layered pigments. | 2008-12-04 |
20080299155 | Color cosmetic compositions for topical anti-aging skin treatment - This invention discloses color cosmetic compositions and methods for anti-aging treatments that utilize plant-based copper antioxidant complexes. | 2008-12-04 |
20080299156 | SKIN CARE COMPOSITIONS CONTAINING A HIGH INTERNAL PHASE EMULSION - The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one fatty compound, capable of forming a liquid crystal; (c) at least one thickening agent; (d) at least one active agent; and (e) water. Also disclosed is a method of treating skin with the above-disclosed skin care composition. | 2008-12-04 |
20080299157 | SKIN CARE COMPOSITIONS HAVING UNIQUE TEXTURE PROPERTIES - The present invention is directed to a skin care composition comprising (a) at least one high internal phase emollient-in-water emulsion; (b) at least one thickening agent; (c) at least one primary emulsifier chosen from a water-in-silicone emulsifier; (d) at least one non-emulsifying silicone elastomer; (e) at least one active agent; and (f) water. Also disclosed is a method of treating skin with the above-disclosed skin care composition. | 2008-12-04 |
20080299158 | FULLY EXTENDED COLOR BULK POWDER, BULK DISPERSION AND METHOD OF USE - The invention provides, among other things, fully and partially extended color bulk powders and partially and fully extended color bulk dispersions. Invention fully and partially extended color powders and fully and partially extended color dispersions can be used in cosmetic and makeup products, personal care products, and pharmaceutical products. | 2008-12-04 |
20080299159 | Anti-acne skin agent for external use - It is an object of the present invention to provide an anti-acne skin agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size, moisturizing properties, and high permeability into skin. The present invention provides an anti-acne skin agent for external use, which comprises protein nanoparticles containing an active ingredient. | 2008-12-04 |
20080299160 | Method of Manufacture of Polymer Composites - A simple and cost effective method of producing a polymer composite comprising a polymer matrix having metal nanoparticles incorporated therein comprises the steps of (i) mixing metal nanoparticles with a polymer dope; and (ii) solidifying the polymer composite from the dope. Antimicrobial fibres are produced by extruding a dope solution ( | 2008-12-04 |
20080299161 | Solid Biocide Composition and Sealed Biocide Article - A solid composition for forming chlorine dioxide on demand and a sealed biocide article. | 2008-12-04 |
20080299162 | Rodenticide Agent - The present invention relates to a rodenticide agent used to exterminate rodents and, more specifically, to an agent embodied as a thermoplastic block having a hardness that will not give to rodent's continuous gnawing. The instant abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way. | 2008-12-04 |
20080299163 | Anti-Fomitic Device Incorporating Anti-Microbial Metals - An anti-fomitic device in the form of a bag or envelope forms a cover for an object for preventing cross-infection by bacteria and other pathogens that may reside on the object. The anti-fomitic device is a flat, flexible bag or envelope with a closure mechanism at one or both ends of the bag or envelope, having a sterile interior that is sealed during manufacture to maintain sterility. Therefore, no outer wrapping for the anti-fomitic device is required. The anti-fomitic device is inverted when used to cover the object and results in an ultimate outer surface that is initially sterile. Materials for the coverings/bags serve as a barrier to the transmission of pathogens. | 2008-12-04 |
20080299164 | Substituted polycaprolactone for coating - A coating formed of a substituted polycaprolactone and method of making and using the same are disclosed. | 2008-12-04 |
20080299165 | Compositions for Treatment of Diseases of the Nail Unit - A flowable composition suitable for use as a controlled release implant, the composition comprising a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid; a biocompatible polar aprotic solvent selected from the group consisting of an amide, an ester, a carbonate, a ketone, an ether, and a sulfonyl; wherein the biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid, and antifungal active. | 2008-12-04 |
20080299166 | NOVEL BIOMATERIALS, THEIR PREPARATION AND USE - The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps:
| 2008-12-04 |
20080299167 | Vascular Endothelial Growth Factors And Methods Of Their Use - Vascular endothelial growth factor alternative splice variants and methods of their use are provided. | 2008-12-04 |
20080299168 | Stabilized Polymeric Delivery System - The invention relates to a delivery system for the sustained and controlled delivery of a group of bioactive agents. More particularly, the invention relates to a delivery system and a method for delivery of a bioactive agent containing a nucleophilic functional group by means of a biodegradable, sustained-release implant. The implant may be a preformed implant, microparticles or an in situ formed implant. The implant includes a biodegradable thermoplastic polymer, the bioactive agent having a nucleophilic group substituent and a stabilizing associate as well as other optional components. The combination of the stabilizing associate with the bioactive agent prevents and/or minimizes and/or lessens degradation of the thermoplastic polymer by the bioactive agent. | 2008-12-04 |
20080299169 | Topographical Templating of Polymeric Materials Using Cellular Morphology - Substrates for influencing the organization, spreading or adhesion of a selected cell to induce or stimulate growth, differentiation or regeneration of the cell or of tissue constituting the cells are provided as well as methods of making such substrates and methods of using such substrates. | 2008-12-04 |
20080299170 | Medical Devices and Coatings Therefor - A coating for a medical device, the device generally being of the type which is to be used internally in a subject, includes a transglutaminase (TGase) inhibitor. The Tgase inhibitor effectively prevents the activity of any Tgase involved in clot formation or clot stability. Preferably, the transglutaminase inhibitor is a factor XIIIa inhibitor. The coating may be prepared by suitable processes such as esterification. The coating may be immobilized on a suitable medical device in a number of ways and is preferably included in a TGase inhibitor containing polymer. The coating may also include a suitable antimicrobial agent. | 2008-12-04 |
20080299171 | GROWTH FACTOR MODIFIED EXTRACELLULAR MATRIX MATERIAL AND METHODS FOR PREPARATION AND USE THEREOF - Described are tissue graft constructs that include submucosa and other extracellular matrix materials that incorporate a number of exogenous proteins. Further described are methods for making tissue graft constructs that include stripping endogenous heparin binding proteins from a porcine graft material and thereafter binding one or more human growth factors to the native heparin molecules that are retained within the graft material. Such graft materials may be used in methods for the treatment of wounds in patients. | 2008-12-04 |
20080299172 | TISSUE REPAIR IMPLANT - An implant is formed from a sheet material and a plurality of microparticles. The sheet may be coated with a mixture of collagen and PMMA beads. The implant may be used to treat many types of defects, including hernias, skin defects, tendon defects, and ulcers. A biocompatible alloplastic mesh implant is stronger and more resistant to infection than typical mesh implants. | 2008-12-04 |
20080299173 | CHONDROCYTE CONTAINER AND METHOD OF USE - Devices and methods for delivering a therapeutic agent produced via a genetically-altered chondrocyte are provided. More specifically, the device includes a housing which defines a cell chamber configured to retain a large volume of chondrocytes while selectively releasing therapeutic agents produced via these entrapped cells. In an exemplary embodiment, the cell chamber can be configured such that a portion of cells can be positioned at least about 1.5 mm from an external wall of the device (i.e., about 1.5 mm away from an external nutrient supply). For example, the cell chamber can have a tubular configuration having a length and a diameter wherein each of these dimensions is at least about 3 mm (thereby the central core to the chamber is at least about 1.5 mm from the outer wall of the device). | 2008-12-04 |
20080299174 | Bis-(Alpha-Amino)-Diol-Diester-Containing Poly (Ester Amide) and Poly (Ester Urethane) Compositions and Methods of Use - The present invention provides biodegradable, biocompatible bis-(α-amino acyl)-diol-diester-containing poly(ester amide) (PEA) and poly(ester urethane) (PEUR) co-polymer compositions with mechanical properties that can be readily tailored by selection of various combinations and proportions of the building blocks of the co-polymers. The compositions are suitable for use in production of drug-releasing biodegradable particles and implantable surgical devices, such as stents and internal fixation devices. The co-polymer compositions, particles and surgical devices biodegrade in vivo by enzymatic action to release bioactive agents in a controlled manner over time as well as biocompatible breakdown products, including one to multiple different amino acids. | 2008-12-04 |
20080299175 | Preparation of Bone Material - The invention provides a bone material having a specific surface area of at least 80 m | 2008-12-04 |
20080299176 | DRUG DELIVERY DEVICE COMPRISING CROSSLINKED POLYURETHANE-SILOXANE-CONTAINING COPOLYMERS - A drug delivery device for placement in the eye includes a drug core comprising a hydrophobic pharmaceutically active agent, and a holder that holds the drug core. The holder is made of a material impermeable to passage of the active agent and includes an opening for passage of the pharmaceutically agent therethrough to eye tissue. The device includes polyurethane-siloxane-containing copolymers crosslinked with hydrophilic monomers. | 2008-12-04 |
20080299177 | Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo - Targeted therapeutic delivery systems comprising specially designed nanocarriers for intracellular therapeutic delivery, mediated by acoustic energy, for use either in vivo or in vitro, are described. Nanocarriers comprised of substantially supramolecular complexes, and mixtures thereof, are used to treat a variety of diseases in humans and other species, such as cancer, opthalmological, pulmonary, urinary or other pathologies. Methods for preparing the targeted therapeutic delivery systems are also embodied, which comprise processing a solution comprised of biopolymers or other species and components, with or without targeting moieties, adding said biopolymers and other compounds to a solution containing one or more therapeutic agents, stabilizing or not stabilizing said nanocarriers, adding one or more contrast agents, and resulting in a targeted therapeutic delivery system. Preferred therapeutics for use with the present invention include nucleic acids, proteins, peptides, and other therapeutic macromolecules. | 2008-12-04 |
20080299178 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION - Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure. | 2008-12-04 |
20080299179 | Solutions for ophthalmic lenses containing at least one silicone containing component - The present invention relates to a method for reducing the occurrence of superficial punctate staining comprising the step of packaging, storing or contacting an uncoated ophthalmic lens comprising at least one polymeric wetting agent and polymer units derived from at least one silicone containing component in a solution comprising an osmolality of about 220 mOsm/kg or greater. | 2008-12-04 |
20080299180 | Peptides based on the sequence of human lactoferrin and their use - The invention relates to new peptides formed of at least seven subsequent amino acids of the amino acids in position 12-40, counted from the N-terminal end, in the sequence constituting human lactoferrin, and preferably modifications thereof. The invention also relates to medicinal products comprising such peptides, especially intended for treatment and prevention of infections, inflammations and tumours. Furthermore, the invention relates to food stuff, e.g. infant formula food, comprising the above mentioned peptides. | 2008-12-04 |
20080299181 | ODOURLESS GARLIC SUPPLEMENT COMPRISING AN ENTERIC COATING AND A DEODORISING LAYER - A garlic supplement comprises one or more cores comprising garlic and an enteric coating encasing the core(s) which is insoluble at pH less than about 5 but soluble at a pH greater than about 5. In one example, the enteric coating comprises a deodorizer. In another example, an external coating is present over the enteric coating and the external coating includes a deodorizer. | 2008-12-04 |
20080299182 | METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY - Formulations of viral vectors for topical application are disclosed as well as methods for making the same. Also disclosed are methods of treating a subject or diagnosing disease in a subject using the formulations of the present invention. | 2008-12-04 |
20080299183 | Patch and patch preparation - The present invention aims at provision of a patch with suppressed occurrence of adhesive residue on the skin after peeling in the presence of water due to perspiration and the like. | 2008-12-04 |
20080299184 | Anticancer agent - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides A cancer-suppressing agent which comprises PCDH20 gene or a homologous gene thereof. | 2008-12-04 |
20080299185 | STABLE DIGESTIVE ENZYME COMPOSITIONS - Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing. | 2008-12-04 |
20080299186 | COATINGS FOR APPLYING SUBSTANCES ONTO SUBSTRATE CARRIER - Compositions of matter containing an active agent, and methods of manufacturing thereof, wherein the method comprises the step of coating a substrate with a coating composition comprising the active agent formulated for immediate release, wherein the coating composition does not contain an appreciable amount of cellulosic materials and preferably comprises polyvinyl alcohol or a polyvinyl alcohol derived copolymer. | 2008-12-04 |
20080299187 | Substances for Reducing Occurence of Major Cardiac Events in Humans - A medicament comprising a dispersion of Red Yeast Rice extract in Omega-3 Oils. The medicament is supplied in capsules such that a daily dose is dispensed in an integral number of capsules. A dispersant is used, preferably Lysine and bamboo. The ratio of Red Yeast Rice Extract to EPA+DHA is in the range between about 1.4 and 2.8. The medicament reduces cholesterol, triglycerides, and reduces serious heart incidents. | 2008-12-04 |
20080299188 | CONTROLLED RELEASE DOSAGE FORMS COMBINING IMMEDIATE RELEASE AND SUSTAINTED RELEASE OF LOW-SOLUBILITY DRUG - A controlled release dosage form comprises an immediate release portion and an enteric coated sustained release core. | 2008-12-04 |
20080299189 | CONTROLLED RELEASE DOPAMINE AGONIST COMPOSITIONS - The present invention relates to a multiphase release oral pharmaceutical formulation having a dopamine agonist as an active ingredient. The multiphase composition comprises at least two different release components. The invention relates to controlled release pharmaceutical compositions of pramipexole or a pharmaceutically acceptable salt thereof for once-daily administration. | 2008-12-04 |
20080299190 | Direct Compression Formulation and Process - This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof; to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process for preparing the tablets by blending the active ingredient and specific excipients into the new formulations and then directly compressing the formulations into the direct compression tablets. The invention also relates to vildagliptin particle size distribution and a new crystal form of vildagliptin particularly adapted for the preparation of improved tablets and other pharmaceutical compositions. | 2008-12-04 |
20080299191 | Fine-Particle Crosslinked Polyvinylpyrrolidone as Tablet Disintegrant - Use of crosslinked polyvinylpyrrolidone with an average particle size of 5-60 μm and a hydration capacity of greater than 7 g/g as tablet disintegrant | 2008-12-04 |
20080299192 | Intraorally Rapidly Disintergrating Tablets and Their Production - The object of the present invention is to provide, as a solid preparation for making it easy to take, thus improving patient's compliance etc., an intraorally rapidly disintegrating tablet which can be produced easily without any particular problem by a usual method of producing tablets with a usual tabletting machine, has practically unproblematic hardness, and disintegrate rapidly in the oral cavity. This tablet is produced by tabletting cores coated with a pharmaceutical disintegrating agent, wherein the core is a granule containing a water-soluble medicament or containing a medicament and a sugar. | 2008-12-04 |
20080299193 | Pharmaceutical composition comprising eszoplicone - The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size. | 2008-12-04 |
20080299194 | Pharmaceutical Formulation For Producing Rapidly Disintegrating Tablets - A pharmaceutical formulation in the form of agglomerates comprising
| 2008-12-04 |
20080299195 | USE OF RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE - This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose. | 2008-12-04 |
20080299196 | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 2008-12-04 |
20080299197 | Triple Combination Release Multi-Layered Tablet - This invention pertains to a multi-layered tablet for a triple combination release of active agents to an environment of use. More particularly, the invention pertains to a multi-layered tablet ( | 2008-12-04 |
20080299198 | Polystyrene sulfonate polymer tablets, their preparation and use - The present invention provides tablets containing at least about 70% of polystyrene sulfonate polymer, binder and moisture. The invention further relates to methods of treating medical conditions including antibiotic-associated diarrhea such as that caused by | 2008-12-04 |
20080299199 | Swellable Dosage Form Comprising Gellan Gum - A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C. In one embodiment of the invention, the particulate matter can be moulded into a desired shape or pressed onto a dispensing unit such as a spoon. | 2008-12-04 |
20080299200 | Oil-in-Water Emulsion for Creating New Product Consistencies - The invention concerns an oil-in-water emulsion wherein the oil droplets of a diameter in the range of 5 nm to hundreds of micrometers exhibit a nano-sized self-assembled structure with hydrophilic domains having a diameter size in the range of 0.5 to 200 nm, due to the presence of a lipophilic additive, and the oil-in-water emulsion contains a thickener or gelling agent in order to create new product consistencies and textures. | 2008-12-04 |
20080299201 | DEVICES, METHODS, AND SYSTEMS FOR ACCESSING NATIVE NEURONS THROUGH ARTIFICIAL NEURAL MEDIATORS (ANMS) - The present invention relates to devices, methods, and systems for accessing native neurons in the nervous system of an animal. Specifically, one or more artificial neural mediators (ANMs) each comprising a neural cell are first formed, and neural connection is then established between the ANMs and one or more native neurons or collections of native neurons located in the nervous system. In this manner, the native neurons or collections of native neurons can be assessed through the ANMs. The neural connection between the ANMs and the native neurons is preferably established by guided axonal growth in the present invention, i.e., either an axon from one of the ANMs is grown into contact with one of the native neurons or collections of native neurons, or an axon from one of the native neurons or collections of native neurons is grown into contact with one of the ANMs. | 2008-12-04 |
20080299202 | Controlled-Delivery System of Pharmacologically Active Substances, Preparation Process and Medical Use Thereof - The invention concerns a system for biocompatible drug release comprising: (i) a polymer matrix; (ii) an inorganic component located inside said matrix and characterized by a lamellar structure with a net positive or negative charge able to intercalate (iii) a pharmacologically active principle into said lamellar structure, by establishing an ionic type of bond with it and thereby obtaining an intercalation compound. The preparation process for the release system comprises the stages of: treating the lamellar solid in such a way as to give it a net positive or negative charge, then combining it with the chosen active principle, also in an ionic form, to obtain an intercalation compound which is then mixed with the polymer matrix. The release system can be employed in making medical devices, like sutures, membranes, osteosynthesis plaques, multilayered devices, gels and drug delivery systems. | 2008-12-04 |
20080299203 | Solid Pharmaceutical Dosage Formulation - The present invention provides a pharmaceutical dosage formulation, and more particularly, a pharmaceutical dosage formulation comprising an HIV protease inhibitor. | 2008-12-04 |
20080299204 | Dosage forms for movement disorder treatment - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual. | 2008-12-04 |
20080299205 | Particulate Constructs For Release of Active Agents - Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments. | 2008-12-04 |
20080299206 | Ophthalmic preparations - The present invention provides ophthalmic formulations containing cyclosporine, methods for preparing the formulation, and methods for using the formulation. | 2008-12-04 |
20080299207 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - Administration of Oxybutynin in nebulized dry powder form directly to a patient's lungs for treating urinary incontinence or respiratory disease. | 2008-12-04 |
20080299208 | Anisometric Particles In The Form Of Nanofibers/Mesofibers,Nanopipes, Nanocables/Mesocables, Nanobands/Mesobands, And The Curved Or Branched Variations Thereof - The invention relates to novel anisometric mesoparticles and nanoparticles in the form of anisometric mesofibers/nanofibers, mesopipes/nanopipes, mesobands/nanobands, mesocables/nanocables, and the curved and branched or superimposed variations thereof as well as a novel method for the production thereof. The invention particularly relates to anisometric mesoparticles and nanoparticles which have an aerodynamic diameter <5 μm, the production thereof, loading thereof with active substances if the same cannot directly be utilized as an active substance, and the use thereof especially for producing medicaments against lung diseases or systemic diseases in humans and animals if the particles cannot directly be utilized as medicaments without carriers. | 2008-12-04 |
20080299209 | Novel Formulations of Fat-Soluble Active Ingredients with High Biovailability - The present invention relates to formulations of a pharmacological effective fat-soluble active ingredient with a high bioavailability of said fat-soluble active ingredient as well as to their manufacture and use as dietary supplement, food, feed, personal care product and/or pharmaceutical. Such formulations are those which when dissolved, dispersed or diluted in/with water have an extinction E 1/1 at a wavelength in the range of from 200 to 800 nm, preferably in the range of from 250 to 600 nm, more preferably in the range of from 250 to 500 nm, more preferably in the range of from 370 to 485 nm, of ≧380, preferably of ≧600, most preferably ≧900. In preferred embodiments of the formulations of the present invention such formulations show an extrusion loss of fat-soluble active ingredient of ≦30% when pressed to tablets. | 2008-12-04 |
20080299210 | STABLE NANOSIZED AMORPHOUS DRUG - Disclosed is a population of nanoparticles, together with methods of making a population of nanoparticles, wherein one or more of the nanoparticles includes: an amorphous drug core having an effective diameter less than or equal to about 2.0 microns, wherein the amorphous drug core is substantially free of dopant, and wherein the amorphous drug core includes a drug with properties that satisfy the following relationships: a glass transition temperature greater than or equal to about 50 Deg. C., a glass forming ability less than or equal to about 0.85; and water solubility at 25 Deg. C. less than or equal to about 1 mg/ml; and at least one stabilizer adsorbed on a surface of the amorphous drug core; and wherein the population of nanoparticles exhibits greater than about six months amorphous stability. | 2008-12-04 |
20080299211 | FEXOFENADINE SUSPENSION FORMULATION - The present invention is directed to an aqueous pharmaceutical suspension of fexofenadine zwitterionic dihydrate Form I. | 2008-12-04 |